Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 690517 + Empagliflozin in Chronic Kidney Disease
NCT06531824Phase 3Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial of vicadrostat in chronic kidney disease (CKD) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Time to first occurrence of the primary composite outcome of: Kidney disease progression, Hospitalization for heart failure, or Cardiovascular death up to 4 years. Started Aug 2024; status: active, not recruiting.
02
Drugs
vicadrostat
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT06531824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06531824.